Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
"Novel transcript, antisense to POTEM" (ENSG00000276888, LOC101929572) is a predicted non-coding RNA annotated on the human genome, identified by its antisense orientation to the POTEM gene locus. This entry is currently uncharacterized in terms of protein coding potential, molecular function, involvement in human biology, or disease. No publications or curated databases assign it any role as a drug target, biomarker, or clinical relevance. Its annotation as "novel transcript" and "antisense to POTEM" indicates it was predicted by transcriptome sequencing but not yet experimentally validated or functionally described. It does *not* fit established categories such as receptor, enzyme, transporter, or transcription factor, nor does it have a known molecular or disease association. Accordingly, this is *not* a target suitable for drug discovery or therapeutic intervention, and its inclusion as a "target" is likely a result of automated annotation without supporting evidence.
Not applicable
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on Novel transcript, antisense to POTEM (ENSG00000276888 (no common abbreviation)).